Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bard set for Gore money soon as Q3 "solid"

This article was originally published in Clinica

Executive Summary

CR Bard had a “solid” third quarter, beating analyst expectations across all divisions and seeing margin expansion, noted Jefferies’ Raj Denhoy. Standout performances came in its vascular and surgical divisions, which saw sales of $209.9m (+4% year-on-year) and $118.1m (+10% year-on-year), versus analyst estimates of $199m and $115m, respectively. The former was driven by its Lutonix drug-eluting balloon, while the latter was helped by the surgical sealant contribution from Neomend, which Bard acquired last year (www.clinica.co.uk, 24 October 2012).

You may also be interested in...



Legal News In Brief

Enzo and Illumina settle patent battle; Bard and Gore argue over jury logistics for an upcoming trial; and former employee alleges False Claims Act violations by medical equipment maker Lincare.

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

Topics

UsernamePublicRestriction

Register

MT101003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel